- Entry
- $58.93
- Final
- $47.41 -19.5%
- Target
- —
- Score
- +1.00
Source: [ https://finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html ](https://finance.yahoo.com/news/obesity-stocks-slump-novos-underwhelming-182728439.html) Shares of obesity drugmakers and developers slid on Tuesday after Novo Nordisk forecast a sharper-than-expected sales decline for 2026, underscoring intensifying competition in the blockbuster weight-loss market. Eli Lilly was down about 4%, Structure Therapeutics fell 6.2%, while Altimmune dropped 4.2%. Viking Therapeutics declined more than 3% and Amgen slipped nearly 1% in afternoon trading. The Danish drugmaker said it expects sales to drop between 5% and 13% this year, compared with analysts' average expectation of …
— ORIGINAL POST ·
Novo Nordisk -14% after forecasting a 5% to 13% sales drop in 2026 and a 14% Q4 profit decline
· r/wallstreetbets
· Feb 3, 2026